LISURIDE AND BROMOCRYPTINE IN L-DOPA STABLE-RESPONDER PARKINSONIAN PATIENTS: A COMPARATIVE, DOUBLE-BLIND EVALUATION OF CARDIOPRESSOR AND NEUROCHEMICAL EFFECTS.